EANS-News: Epigenomics AG / Epigenomics AG Provides Update on Financing Plans

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Subtitle: Not for distribution in the United States

Restructuring & Recapitalisations/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A. (euro adhoc) - Epigenomics
AG (Frankfurt Prime Standard: ECX), the German-American cancer
molecular diagnostics company, today announced the intention to
launch a capital increase by way of a rights issue in January 2013.
With the capital increase the Company plans to generate gross
proceeds of up to just under EUR 5 million and aims to extend the
cash runway of the Company at least into Q4 2013.

In line with previous announcements, and supported by the recently
published results of a comparison study of the company's lead CRC
screening product Epi proColon® to fecal immunochemical testing
(FIT), Epigenomics will continue to explore all strategic options for
the Company in its further development, especially including the
option of securing additional financial resources to support the
Company's operations up to and beyond a potential U.S. Food and Drug
Administration (FDA) approval for Epi proColon® in 2013.

Dr. Thomas Taapken, Chief Financial Officer and acting Chief
Executive Officer of Epigenomics, commented: "We are very thankful to
our shareholders who supported the development of the Company and its
lead product Epi proColon® over the last years. The recently
announced results of the comparison study to FIT are a major
milestone for Epigenomics that enable us to move ahead with our
Premarket Approval (PMA) filing with FDA as planned before the end of
2012. The contemplated transaction is in our view in the best
interest the Company and its shareholders at this time, as it brings
the Company closer to potential FDA approval for Epi proColon®, while
alleviating the current financial situation of the Company."

Transaction outline: Epigenomics Executive Board, with the approval
of the Supervisory Board, has taken the decision to implement an
increase of the issued share capital by utilization of authorized
capital. The capital increase shall be carried out by way of a rights
issue against cash contributions. It shall be structured in such a
manner that the gross proceeds generated under the capital increase
will amount to up to just under EUR 5,000,000 in order to make use of
the available exemption from the publication of a prospectus under
German securities laws.

The Supervisory and Executive boards of the Company plan to resolve
the details of the capital increase in early January 2013, in
particular the maximum number of new shares and the subscription
ratio, which will then be published by way of an ad hoc announcement
without undue delay. Publication of the subscription offer and
beginning and end of the subscription period will subsequently take
place in line with German market practice.

The new shares will first be offered to the shareholders of the
Company. Shares not taken up by shareholders might subsequently be
offered in a private placement to institutional investors.

Epigenomics AG intends to use the net proceeds from the offering to
finance its current operations and to build and strengthen the
distribution capacities for its products.

Recent events and outlook The Company recently announced results of
the head-to-head comparison study between its blood-based Epi
proColon® and FIT for the detection of colorectal cancer and remains
to be on track to file the final module of the PMA submission with
the FDA before the end of this year. A subsequent decision by the FDA
on the PMA submission for Epi proColon® is expected during the second
half of 2013.

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics Epigenomics (www.epigenomics.com) is a molecular
diagnostics company developing and commercializing a pipeline of
proprietary products for cancer. The Company's products enable
doctors to diagnose cancer earlier and more accurately, leading to
improved outcomes for patients. Epigenomics' lead product, Epi
proColon®, is a blood-based test for the early detection of
colorectal cancer, which is currently marketed in Europe and is in
development for the U.S.A. The Company's technology and products have
been validated through multiple partnerships with leading global
diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations
in Europe and the U.S.A.

Epigenomics legal disclaimer This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English